Regenxbio Inc RGNX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
16.83UNCH (UNCH)
Volume
7,367
Close
16.83quote price arrow up+0.19 (+1.14%)
Volume
232,498
52 week range
11.83 - 28.80
Loading...
  • Open17.24
  • Day High17.52
  • Day Low16.68
  • Prev Close16.64
  • 52 Week High28.80
  • 52 Week High Date03/05/24
  • 52 Week Low11.83
  • 52 Week Low Date02/02/24

Key Stats

  • Market Cap825.389M
  • Shares Out49.04M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-6.24

KEY STATS

  • Open17.24
  • Day High17.52
  • Day Low16.68
  • Prev Close16.64
  • 52 Week High28.80
  • 52 Week High Date03/05/24
  • 52 Week Low11.83
  • 52 Week Low Date02/02/24
  • Market Cap825.389M
  • Shares Out49.04M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.35
  • YTD % Change-6.24

RATIOS/PROFITABILITY

  • EPS (TTM)-6.03
  • P/E (TTM)-2.79
  • Fwd P/E (NTM)-3.75
  • EBITDA (TTM)-250.808M
  • ROE (TTM)-63.65%
  • Revenue (TTM)90.242M
  • Gross Margin (TTM)58.76%
  • Net Margin (TTM)-291.99%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/08/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Regenxbio Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational...
Allan Fox J.D.
Chairman of the Board
Kenneth Mills
President, Chief Executive Officer, Director
Curran Simpson
Chief Operating Officer, Executive Vice President
Vittal Vasista
Chief Financial Officer, Executive Vice President
Patrick Christmas II
Executive Vice President, Chief Legal Officer
Address
9804 Medical Center Drive
Rockville, MD
20850
United States

Top Peers

SYMBOLLASTCHG%CHG
SAGE
SAGE Therapeutics Inc
13.94+0.83+6.37%
YMAB
Y-mAbs Therapeutics Inc
17.15-0.10-0.58%
IMTX
Immatics NV
10.77-0.12-1.10%
NRIX
Nurix Therapeutics Inc
12.78+0.05+0.39%
MGNX
MacroGenics Inc
15.67+0.45+2.96%